Betahistine: What It Really Can Do in Ménière's Disease — and What It Can't

1. At a glance: technical data sheet

2. How it works: a histamine derivative for the inner ear

In Germany, betahistine is approved for vertigo in Ménière's disease; some products explicitly name the whole symptom complex of vertigo, ear noises and hearing loss.^¹ It is not approved for other forms of dizziness, such as benign positional vertigo or dizziness in older age. What Ménière's disease is, how it differs from other causes and how it is diagnosed is described in detail in the article on the condition; here the focus is on the medicine.

Just for context: typical of Ménière's are recurring attacks of spinning vertigo lasting from 20 minutes to 12 hours, together with fluctuating hearing loss, ringing in the ears or a feeling of pressure in the ear on the affected side.^² The inner ear often shows a build-up of inner ear fluid (endolymphatic hydrops); why it develops is not fully understood.

Chemically, betahistine resembles histamine, a messenger substance the body makes itself. According to the SmPC, exactly how it works is only partly understood. Several mechanisms are being discussed, mostly based on animal experiments:^¹

• Histamine system: betahistine acts as a partial activator of the H1 receptor and as a blocker of the H3 receptor. This releases more histamine in the nervous system.
• Blood flow: in animal experiments it improved blood flow in certain vessels of the inner ear.
• Balance centres: it dampens activity in the vestibular nuclei of the brainstem in a dose-dependent way and, in animals, made it easier for the brain to adapt after the balance organ failed.

This profile leads to the two things you should know about betahistine. First: it is a medicine for long-term treatment, aimed at making attacks less frequent and less severe — it does not end a vertigo attack that is already under way. Second: because it resembles histamine, this explains the most important precautions — with stomach ulcers, asthma, hives and the rare phaeochromocytoma.

3. Dosing: up to 48 mg a day, spread out

The following information describes the Summary of Product Characteristics (SmPC) and is not a recommendation for use. The dose and duration are set by the treating practice.^¹

• Adults: according to the SmPC, the usual maintenance dose is 24 to 48 mg betahistine dihydrochloride per day, divided into two or three single doses. Some products give a starting dose of 16 mg three times a day.
• Maximum dose: the daily dose should not exceed 48 mg.
• Children and adolescents under 18: use is not recommended because there are not enough data.
• Older people, kidney and liver impairment: there are only limited study data; no fixed dose adjustment is specified, and some SmPCs recommend caution.

The German S2k guideline for general practice, “Dizziness in the GP practice” (DEGAM, the German College of General Practitioners and Family Physicians), also gives up to 48 mg per day for Ménière's disease, split into several single doses, and explicitly notes that the evidence so far is weak.^³ In studies and in practice, considerably higher doses have sometimes been tried. This lies outside the approved use and, as section 6 shows, is not supported by studies; in its current version, the guideline has removed earlier references to higher doses.^³

4. Taking it: with food, regularly, with patience

In everyday life, betahistine is an uncomplicated medicine. The key points:

1. During or after meals. That is what the SmPC says. Total absorption is similar with and without food; with food the active ingredient is simply absorbed more slowly — and your stomach tolerates it better.^¹ More on this in Medications before or after eating.
2. Spread over the day. Because the body breaks betahistine down quickly, the daily dose is split into two or three doses, for example with breakfast, lunch and dinner. Linking it firmly to mealtimes makes it easier not to forget a dose.
3. Swallowed whole with water. According to the SmPC, the score line on many tablets is only there to make swallowing easier, not to divide them into equal doses — unless the product explicitly allows it.
4. Missed dose: do not double up. As a rule, the next dose is taken at the usual time; the basics are covered in Missed a medication.
5. Keep an attack diary. Note the date, duration and severity of every vertigo attack, along with ear noises, how your hearing feels and possible triggers. Only then can you honestly judge after a few months whether anything has changed.

5. Side effects: mostly stomach and head

Betahistine is considered well tolerated. According to the SmPC, only a few side effects occurred more often than with a dummy medicine in placebo-controlled studies.^¹

Tiredness is not a typical problem: in studies on fitness to drive, betahistine had no or only a negligible effect. Some SmPCs do, however, point out that drowsiness is possible.^¹ When it comes to driving, the condition usually matters more than the medicine anyway — a sudden attack of spinning vertigo at the wheel is dangerous. More on this in Medications and driving.

6. What betahistine really does in Ménière's: the evidence

This is the heart of this article. Betahistine has been prescribed for decades, and many people report that their attacks became less frequent while taking it. The SmPC refers to studies in which the severity and frequency of vertigo attacks improved.^¹ Most of these studies, however, were small, short and methodologically open to criticism. What more rigorous research shows is more sobering.

The BEMED trial: no difference from placebo

The largest placebo-controlled long-term trial to date was carried out at German centres. 221 people with Ménière's disease received either a dummy medicine, 24 mg betahistine twice a day or 48 mg three times a day for nine months — the latter being three times the approved maximum dose. Result: the number of vertigo attacks fell considerably in all three groups, but no more with betahistine than with placebo, not even at the high dose. Tolerability was good in all groups.^⁴

The Cochrane review: benefit uncertain

A Cochrane review from 2023 summarised the studies on medicines for Ménière's disease. For betahistine, it concludes that its benefit is uncertain; the certainty of the available evidence is mostly low to very low.^⁵ The DEGAM guideline adopts this assessment: for all medicines studied so far for prevention, explicitly including betahistine at the doses studied, effectiveness is uncertain or very uncertain.^³

Why experience and studies differ

The most important reason is already stated in the BEMED trial: Ménière's disease runs in phases. People who start treatment because of a cluster of attacks often go through a calmer phase afterwards anyway — with or without an active ingredient. Without a comparison group, this looks like treatment success. On top of that come expectation effects and the fact that stress, sleep and lifestyle are often tackled at the same time.